Trapp Bruce D, Nave Klaus-Armin
Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Annu Rev Neurosci. 2008;31:247-69. doi: 10.1146/annurev.neuro.30.051606.094313.
Multiple sclerosis (MS) is an inflammatory-mediated demyelinating disease of the human central nervous system. The clinical disease course is variable, usually starts with reversible episodes of neurological disability in the third or fourth decade of life, and transforms into a disease of continuous and irreversible neurological decline by the sixth or seventh decade. We review data that support neurodegeneration as the major cause of irreversible neurological disability in MS patients. We question whether inflammatory demyelination is primary or secondary in the disease process and discuss the challenges of elucidating the cause of MS and developing therapies that will delay or prevent the irreversible and progressive neurological decline that most MS patients endure.
多发性硬化症(MS)是一种由炎症介导的人类中枢神经系统脱髓鞘疾病。其临床病程多变,通常在人生的第三个或第四个十年开始出现可逆的神经功能障碍发作,并在第六个或第七个十年转变为持续且不可逆的神经功能衰退疾病。我们回顾了支持神经退行性变是MS患者不可逆神经功能障碍主要原因的数据。我们质疑炎症性脱髓鞘在疾病过程中是原发性还是继发性的,并讨论了阐明MS病因以及开发能够延缓或预防大多数MS患者所经历的不可逆和进行性神经功能衰退的疗法所面临的挑战。